Wedbush Research Analysts Raise Earnings Estimates for BEAM

Beam Therapeutics Inc. (NASDAQ:BEAM) – Analysts at Wedbush raised their Q1 2025 earnings estimates for Beam Therapeutics in a note issued to investors on Monday, March 10th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($1.00) per share for the quarter, up from their previous forecast of ($1.21). Wedbush currently has a “Outperform” rating and a $57.00 price objective on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($0.97) EPS, Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($4.02) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($5.07) EPS, FY2028 earnings at ($4.02) EPS and FY2029 earnings at $0.57 EPS.

Beam Therapeutics (NASDAQ:BEAM) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping analysts’ consensus estimates of ($1.25) by $0.16. The firm had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company’s revenue was down 90.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.73 earnings per share.

Several other research firms also recently issued reports on BEAM. Cantor Fitzgerald restated an “overweight” rating on shares of Beam Therapeutics in a research note on Wednesday. Scotiabank upgraded shares of Beam Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $40.00 price objective for the company in a research note on Monday. Sanford C. Bernstein upgraded shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 7th. Guggenheim restated a “buy” rating and issued a $78.00 price objective on shares of Beam Therapeutics in a research note on Thursday, February 27th. Finally, Jones Trading raised shares of Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 target price for the company in a report on Monday. Two research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $50.82.

Beam Therapeutics Price Performance

NASDAQ BEAM opened at $25.06 on Thursday. Beam Therapeutics has a 1 year low of $20.84 and a 1 year high of $37.42. The company has a market capitalization of $2.10 billion, a PE ratio of -14.24 and a beta of 1.91. The company has a fifty day moving average of $27.11 and a two-hundred day moving average of $26.03.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC increased its holdings in Beam Therapeutics by 0.4% in the fourth quarter. Farallon Capital Management LLC now owns 8,239,123 shares of the company’s stock valued at $204,330,000 after buying an additional 31,000 shares in the last quarter. ARK Investment Management LLC grew its position in shares of Beam Therapeutics by 8.2% in the fourth quarter. ARK Investment Management LLC now owns 7,068,029 shares of the company’s stock valued at $175,287,000 after purchasing an additional 536,930 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Beam Therapeutics by 11.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock valued at $98,149,000 after purchasing an additional 404,782 shares during the last quarter. Nikko Asset Management Americas Inc. grew its position in shares of Beam Therapeutics by 11.4% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company’s stock valued at $98,109,000 after purchasing an additional 404,782 shares during the last quarter. Finally, State Street Corp grew its position in shares of Beam Therapeutics by 12.5% in the third quarter. State Street Corp now owns 3,929,557 shares of the company’s stock valued at $96,274,000 after purchasing an additional 437,402 shares during the last quarter. 99.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Beam Therapeutics

In other Beam Therapeutics news, insider Christine Bellon sold 1,241 shares of the stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the transaction, the insider now directly owns 102,968 shares of the company’s stock, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO John M. Evans sold 30,000 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the completion of the transaction, the chief executive officer now directly owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. This trade represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is currently owned by corporate insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.